Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2026)
Lyell Immunopharma recorded quarterly Profit After Tax of -$24.2 million in Q1 2026, up 82.84% quarter-over-quarter from -$140.7 million in Q4 2025, and up 53.73% year-over-year from -$15.7 million in Q1 2025.
Lyell Immunopharma's Profit After Tax history runs 7 years deep, the most recent figure standing at -$24.2 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 53.73% year-over-year to -$24.2 million; the TTM figure through Mar 2026 stood at -$246.4 million (up 26.34% YoY), while the FY2025 annual figure was -$274.4 million, up 19.98% from the prior year.
- Profit After Tax came in at -$24.2 million for Q1 2026 at Lyell Immunopharma, up from -$140.7 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$8.4 million in Q4 2022 to a low of -$191.9 million in Q4 2024.
- A 5-year average of -$62.3 million and a median of -$52.2 million in 2025 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax surged 89.97% in 2022 and plunged 530.34% in 2023, its largest moves.
- Lyell Immunopharma's Profit After Tax stood at -$8.4 million in 2022, then slumped by 530.34% to -$52.9 million in 2023, then sank by 262.62% to -$191.9 million in 2024, then advanced by 26.68% to -$140.7 million in 2025, then soared by 82.84% to -$24.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$24.2 million, -$140.7 million, and -$38.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | -24.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.15 Mn |
| Dec 31, 2025 | -140.72 Mn |
| Sep 30, 2025 | -38.85 Mn |
| Jun 30, 2025 | -42.68 Mn |
| Mar 31, 2025 | -52.20 Mn |
| Dec 31, 2024 | -191.94 Mn |
| Sep 30, 2024 | -44.58 Mn |
| Jun 30, 2024 | -45.81 Mn |
| Mar 31, 2024 | -60.67 Mn |
| Dec 31, 2023 | -52.93 Mn |
| Sep 30, 2023 | -50.85 Mn |
| Jun 30, 2023 | -63.89 Mn |
| Mar 31, 2023 | -66.96 Mn |
| Dec 31, 2022 | -8.40 Mn |
| Sep 30, 2022 | -70.25 Mn |
| Jun 30, 2022 | -36.32 Mn |
| Mar 31, 2022 | -68.14 Mn |
| Dec 31, 2021 | -83.71 Mn |
| Sep 30, 2021 | -48.88 Mn |
| Jun 30, 2021 | -62.60 Mn |
| Mar 31, 2021 | -55.04 Mn |
| Dec 31, 2020 | -38.86 Mn |
| Sep 30, 2020 | -35.72 Mn |
| Jun 30, 2020 | -100.66 Mn |